|
1. Eli Lilly claims its GLP-1 outperforms semaglutide in trial Full story
2. FDA approves 1st Barth syndrome treatment Full story
3. New protocols + EHRs are falling short on inpatient diabetes care. Why and what to do here.
4. White House weighs exemptions on H-1B visa fees for physicians Full story
5. 5 GLP-1 updates Full story
6. Fewer resources, same needs. How 4 systems use AI to protect care access here.
7. FDA warns drugmakers over advertising practices Full story
8. 6 drugs in shortage Full story
Becker's Learning Opportunities
9. From waitlists to warm handoffs: Banner's integrated primary care model in focus here.
10. Reimbursement pressure is shifting post-acute priorities — how payer + provider leaders are responding, here.
11. Some ED visits qualify for higher third-party payments. Are yours flagged? Find out here.
12. Interested in more? See Becker’s full lineup of
webinars
and
whitepapers.
|
.png)
.png)
